ArticleClinicoEconomics and outcomes research : CEOR2022

Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England.

Adrian Kilcoyne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.